#United States #Boston #Fertility #Granata Bio #Gedeon Richter

Granata Bio and Gedeon Richter: A Strategic Collaboration in Women's Health

Granata Bio, a prominent U.S.-based biotechnology company dedicated to advancing fertility therapies, has officially announced its strategic partnership with Gedeon Richter Plc., a leading firm in women's health. This collaboration marks a significant milestone in both companies' missions to enhance the fertility landscape in the United States.

A Significant Investment

Under this partnership, Gedeon Richter has acquired a substantial equity stake in Granata Bio while also appointing a member to Granata's Board of Directors. This close collaboration aims to leverage both companies' strengths—Granata's extensive knowledge of the U.S. fertility market and Richter's global manufacturing capabilities and experience.

Richter's press release revealed the strategic significance of this partnership, emphasizing the importance of expanding its presence in the U.S. and reinforcing its Women's Health Care portfolio. The combination of Granata's U.S. market expertise and Richter's international experience presents a formidable alliance geared towards improving accessibility to fertility treatments.

Co-Development of Cutting-Edge Therapies

In addition to financial investment, the two firms have also agreed to a binding term sheet for the co-development of BEMFOLA®, a recombinant follicle-stimulating hormone (FSH) intended for the U.S. market. This collaboration will allow Granata to broaden its portfolio while participating in a royalty purchase agreement for Granata's proprietary human menopausal gonadotropin (hMG) program. The partnership aligns both companies' long-term commercial objectives in the evolving fertility sector.

Evan Sussman, CEO and Co-Founder of Granata Bio, expressed his enthusiasm about this partnership, stating, "We are proud to partner with Gedeon Richter, which brings global reach and manufacturing excellence to complement our strengths in the U.S. market. Together, we will deliver better access to fertility care to those who need it most."

Supporting this sentiment, Stephen Medeiros, Chief Operating Officer of Granata Bio, emphasized the critical role of BEMFOLA® in ovarian stimulation treatment, noting, "FSH is the most prescribed gonadotropin by volume. The addition of BEMFOLA to our pipeline solidifies our position across all major IVF product categories, which is particularly beneficial for patients and healthcare providers in the U.S."

Expanding Granata's Market Leadership

This partnership follows Granata's recent acquisition of Oviva Therapeutics, further enhancing its position in the fertility market. By combining their innovative assets, both companies are strategically poised to offer a diverse range of effective solutions aimed at improving patient outcomes and access within reproductive care.

Granata Bio, established in 2018, has dedicated itself to advancing women's health and infertility therapies. The company has developed a pipeline of innovative products that target unmet medical needs in reproductive medicine. Granata is also the parent company of Oviva Therapeutics, which focuses on creating first-of-its-kind therapeutics that aim to preserve ovarian function and extend women's health span. This integrated approach reflects their commitment to tackling the complexities surrounding fertility and reproductive health.

In conclusion, the partnership between Granata Bio and Gedeon Richter signifies a promising advancement in the fertility sector. As these two industry leaders come together, their collaboration serves as a beacon of hope for individuals seeking reproductive health solutions. With the combined strengths of both companies, the future development of fertility therapeutics appears bright, potentially transforming the landscape of women's health in the U.S.